Skip to main content
SpringerLink
Log in
Book cover

45 Jahre Herzinfarkt- und Fettstoffwechselforschung pp 137–150Cite as

Thrombozytenaggregationshemmer bei koronarer Herzkrankheit

  • Conference paper

Zusammenfassung

Der Beitrag beschäftigt sich mit einer zunächst umstrittenen, lange kaum akzeptierten, heute jedoch mehr und mehr sich durchsetzenden pharmakotherapeutischen Maßnahme bei koronarer Herzkrankheit: dargestellt werden soll der heutige Stand der Anwendung von Thrombozytenaggregationshemmern bei dieser Erkrankung. Allerdings steht man vor der Schwierigkeit, dabei den Reiter nennen zu können, ohne das Roß zu kennen. Liegt dem erfolgreichen Einsatz dieser Substanzklasse tatsächlich die Hemmung der Thrombozytenaggregation zugrunde?

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AMIS — Aspirin Myocardial Infarction Study Research Group (1980) A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243: 661–669

    Article  Google Scholar 

  • ARIS — Anturan Reinfarction Italian Study Group (1982) Sulfinpyrazone in post-myocardial infarction. Lancet I: 237–242

    Google Scholar 

  • ART — Anturan Reinfarction Trial Research Group (1980) Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302: 250–256

    Article  Google Scholar 

  • Beaufils M, Uzan S, Donsimoni R, Colau JC (1985) Prevention of pre-eclampsia by early platelet therapy. Lancet I: 840–842

    Article  Google Scholar 

  • Brooks N, Wright J, Sturridge M, Pepper J, Magee P, Walesby R, Layton C, Honey M, Balcon R (1985) Randomized placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion. Br Heart J 53: 201–207

    Article  PubMed  CAS  Google Scholar 

  • Brown BG, Cukingnan RA, DeRouen T, Goede LV, Wong M, Fee HJ, Roth JA, Carey JS (1985) Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation 72: 138–146

    Article  PubMed  CAS  Google Scholar 

  • Busse WD, Seuter F (1981) Erfahrungen mit Acetylsalicylsäure, Dipyridamol und Sulfinpyrazon in verschiedenen Tiermodellen. In: Breddin HK, Gross D, Rotter W (Hrsg) Thrombosemodelle am Tier. Die Rolle der Prostaglandine für Thrombogenese und Schmerzpathogenese. Schattauer, Stuttgart

    Google Scholar 

  • Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH (1985) Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 313: 1369–1375

    Article  PubMed  CAS  Google Scholar 

  • Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes DR, Vlietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK (1982) A platelet-inhibitor-drug trial in coronary-artery bypass operations : benefit of perioperative dipyradamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 307: 73–78

    Article  PubMed  CAS  Google Scholar 

  • Elwood PC, Sweetnam PM (1979) Aspirin and secondary mortality after myocardial infarction. Lancet H: 1313–1315

    Article  Google Scholar 

  • Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R (1974) A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br J Med I: 436–440

    Article  Google Scholar 

  • FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration in man. J Clin Invest 71: 676–688

    Article  PubMed  CAS  Google Scholar 

  • Fröhli P, Graf Ch, Rhyner K (1983) Die Prophylaxe vaskulärer Komplikationen bei Polycythaemia vera und primärer Thrombozythämie mit niedrig dosierter Acetylsalicylsäure. Schweiz Med Wochenschr 113: 1622–1627

    PubMed  Google Scholar 

  • German-Austrian Study — Breddin K, Loew D, Lechner K, Überla K, Walter E (1980) Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 9: 325–344

    PubMed  Google Scholar 

  • Haarmann W (1981) Erfahrungen mit Acetylsalicylsäure, Dipyridamol und Sulfinpyrazon in verschiedenen Tiermodellen. In: Breddin HK, Gross D, Rotter W (Hrsg) Thrombosemodelle am Tier. Die Rolle der Prostaglandine für Thrombogenese und Schmerzpathogenese. Schattauer, Stuttgart S 173–187

    Google Scholar 

  • Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA (1979) Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med: 301: 577–579

    Article  PubMed  CAS  Google Scholar 

  • Holmsen H, Weiss HJ (1979) Secretable storage pools in platelets. Ann Rev Med 30: 119–134

    Article  PubMed  CAS  Google Scholar 

  • Klimt ChR, Knatterud GL, Stamler R, Meier P (1986) Persantine-aspirin reinfarction study, Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol: 251–269

    Google Scholar 

  • Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Puget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309: 396–403

    Article  PubMed  Google Scholar 

  • Lorenz RL, Schacky CV, Weber M, Meister W, Kotzur J, Reichardt B, Theisen K, Weber PC (1984) Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Lancet 1:1261–1264

    Article  PubMed  CAS  Google Scholar 

  • Maurin N (1986) Niedrig dosierte Acetylsalicylsäure (“Low-Dose-ASA”). Med Welt 37:1329–1334

    Google Scholar 

  • Mayer JE, Lindsay WG, Castaneda W, Nicoloff DM (1981) Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts. Ann Thorac Surg 31: 204–210

    Article  PubMed  Google Scholar 

  • McEnany MT, Salzman EW, Mundth ED, DeSanctis RW, Harthorne JW, Weintraub RM, Gates S, Austen WG (1982) The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg 83: 81–89

    PubMed  CAS  Google Scholar 

  • Moncada S, Gryglewski RJ, Bunting GS, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663–665

    Article  PubMed  CAS  Google Scholar 

  • Pantely GA, Goodnight SH, Rahimtoola SH, Harlan BJ, DeMots H, Calvin L, Rösch J (1979) Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary artery bypass. N Engl J Med 301: 962–966

    Article  PubMed  CAS  Google Scholar 

  • PARIS I: Persantine-Aspirin Reinfarction Study Research Group (1980) Persantine and aspirin in coronary heart disease. Circulation 62: 449–461

    Google Scholar 

  • Patrignani P, Filabozzi P, Patrono C (1983) Low-dose aspirin is a selective inhibitor of platelet cycloocygenase activity in healthy subjects. Adv Prostaglandin. Thromboxane Leukotriene Res 11: 259–264

    CAS  Google Scholar 

  • Preston FE (1983) Aspirin, prostaglandins, and peripheral gangrene. Am J Med 74, No 6 A: 55–60

    Article  PubMed  CAS  Google Scholar 

  • Rajah SM, Salter MCP, Donaldson DR, Subba Rao R, Boyle RM, Partridge JB, Watson DA (1985) Acetylsalicylic acid and dipyridamole improve the early patency of aortacoronary bypass grafts. J Thorac Cardiovasc Surg 80: 373–377

    Google Scholar 

  • Seuter F (1976) Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors. Haemostasis 5: 85

    PubMed  CAS  Google Scholar 

  • Seuter F, Busse WD (1981) Möglichkeiten und Grenzen der Standardisierung von Thrombosemodellen am Tier. In: Breddin K, Gross D, Rotter W (Hrsg): Thrombosemodelle am Tier. Schattauer, Stuttgart; S 31–44

    Google Scholar 

  • Sharma GVRK, Khuri SF, Josa M, Folland ED, Parisi AF (1983) The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation 68 [Suppl II] 218–221

    Google Scholar 

  • Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP (1981) Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Ann J Cardiol 48: 395–402

    Article  CAS  Google Scholar 

  • The Coronary Drug Project Research Group (1976) Aspirin in coronary heart disease. J Chron Dis 29: 625–642

    Article  Google Scholar 

  • Wallenburg HCS, Dekker GA, Makovitz JE, Rotmans P (1986) Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet I: 1–3

    Article  Google Scholar 

  • Walter E, Weber E (1981) Thrombozytenaggregation, Physiologie und pharmakologische Beeinflussung. Hämostaseologie 1: 73–86

    CAS  Google Scholar 

  • Walter E, Schumacher CH, Staiger CH, Zimmermann R, Weber E (1983) Wirkung einer einwöchigen Thromboxansynthese-Hemmung mit täglich 400 mg Dazoxiben. DAB-Tagung Poster

    Google Scholar 

  • Weber E (1984) Problematik des Wirksamkeitsnachweises von Aggregationshemmern. Münch Med Wschr 126: 336–340

    Google Scholar 

  • Weichert W, Breddin HK (1985) Antithrombotic effect of acetylsalicylic acid (ASA) and pentoxifylline in laser-induced thromboses in rat mesenteric vessels. VASA 14: 280–284

    PubMed  CAS  Google Scholar 

  • Weiss HJ, Aledort LM (1967) Impaired platelet/connective tissue reaction in man after aspirin ingestion. Lancet II: 495–497

    Article  Google Scholar 

  • Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian K, Tack-Goldman K, Gay WA (1983) Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308: 800–805

    Article  PubMed  CAS  Google Scholar 

  • Zimmermann R, Hof M, Andrassy K (1983) Untersuchungen zur Thrombusbildung unter maximaler Hemmung der Thrombozytenfunktion. In: Breddin HK (Hrsg): Prostaglandine und Plättchenfunktion. Schattauer, Stuttgart, S 195–205

    Google Scholar 

Download references

Authors
  1. E. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinischen Klinik Diakonissenkrankenhaus Mannheim, Akademisches Lehrkrankenhaus der Universität Heidelberg, Speyerer Straße 91-93, 6800, Mannheim, Germany

    Hubert Mörl (Chefarzt) (Chefarzt)

  2. Med. Univ. Klinik, Bergheimer Straße 58, 6900, Heidelberg, Germany

    Curt Diehm (Oberarzt) (Oberarzt)

  3. Dr. Karl Thomae GmbH, Birkendorfer Straße 65, 7950, Biberach/Riß, Germany

    Gerhard Heusel

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Weber, E. (1988). Thrombozytenaggregationshemmer bei koronarer Herzkrankheit. In: Mörl, H., Diehm, C., Heusel, G. (eds) 45 Jahre Herzinfarkt- und Fettstoffwechselforschung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73440-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73440-3_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-18945-9

  • Online ISBN: 978-3-642-73440-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation